Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNeuropharmacology

Pharmacologic activity of substituted tryptamines at 5-HT2AR, 5-HT2CR, 5-HT1AR, and SERT

Laura B Kozell, Amy J. Eshleman, Tracy L Swanson, Shelley H Bloom, Katherine M Wolfrum, Jennifer L Schmachtenberg, Randall J Olson, Aaron J. Janowsky and Atheir I Abbas
Journal of Pharmacology and Experimental Therapeutics January 20, 2023, JPET-AR-2022-001454; DOI: https://doi.org/10.1124/jpet.122.001454
Laura B Kozell
1Psychiatry, Oregon Health & Sciences University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy J. Eshleman
2Research Service (R & D 22), VA Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tracy L Swanson
3OHSU, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shelley H Bloom
4VAPORHCS, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine M Wolfrum
5VAMC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L Schmachtenberg
4VAPORHCS, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randall J Olson
6Oregon Health & Science University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron J. Janowsky
7Department of Psychiatry, Oregon Health & Science University, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atheir I Abbas
8Veterans Affairs Portland Health Care System, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Atheir I Abbas
  • For correspondence: abbasat@ohsu.edu
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied, under medical guidance, as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using HEK cells stably expressing 5-HT1A, 5-HT2A, and 5-HT2C receptors (5-HT1AR, 5-HT2AR, 5HT2CR respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT2AR, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT2CR, 5-HT1AR, and SERT. Sorting by the ratio of 5-HT2A to 5-HT2C, 5-HT1A, or SERT affinity revealed chemical determinants of selectivity. We found that while 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT2ARs versus 5-HT1ARs and 5-HT2CRs. 5-substituted compounds exhibited high affinities for 5-HT1ARs, low affinities for 5-HT2C­Rs, and a range of affinities for 5-HT2ARs, resulting in selectivity for 5-HT2ARs versus 5-HT2CRs but not versus 5-HT1ARs. Additionally, a number of psychedelics bound to SERT, with non-ring substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT2ARs compared to 5-HT2CRs and 5-HT1ARs. Conversely, coupling efficiency/amplification ratio was highest at 5-HT2ARs in comparison to 5-HT2CRs and 5-HT1ARs.

Significance Statement Synthetic substituted tryptamines represent both potential public health threats and potential treatments of psychiatric disorders. The substituted tryptamines tested differed in affinities, potencies and efficacies at 5-HT2A, 5-HT2C and 5HT1A receptors and the serotonin transporter (SERT). Several compounds were highly selective for and coupled very efficiently downstream of 5-HT2A versus 5-HT1A and 5-HT2C receptors, and some bound SERT. This basic pharmacology of substituted tryptamines aids our understanding of the pharmacologic basis for their potential for harm and as therapeutic agents.

  • g protein-coupled receptors (GPCRS)
  • Hallucinogens
  • serotonin receptors
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacologic activity of substituted tryptamines at 5-HT2AR, 5-HT2CR, 5-HT1AR, and SERT
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNeuropharmacology

Substituted tryptamine activity at 5-HT receptors & SERT

Laura B Kozell, Amy J. Eshleman, Tracy L Swanson, Shelley H Bloom, Katherine M Wolfrum, Jennifer L Schmachtenberg, Randall J Olson, Aaron J. Janowsky and Atheir I Abbas
Journal of Pharmacology and Experimental Therapeutics January 20, 2023, JPET-AR-2022-001454; DOI: https://doi.org/10.1124/jpet.122.001454

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherNeuropharmacology

Substituted tryptamine activity at 5-HT receptors & SERT

Laura B Kozell, Amy J. Eshleman, Tracy L Swanson, Shelley H Bloom, Katherine M Wolfrum, Jennifer L Schmachtenberg, Randall J Olson, Aaron J. Janowsky and Atheir I Abbas
Journal of Pharmacology and Experimental Therapeutics January 20, 2023, JPET-AR-2022-001454; DOI: https://doi.org/10.1124/jpet.122.001454
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • In Vivo SRI-32743 Attenuates Tat Effects on Extracellular DA
  • Kv7 Opener Attenuates Seizures and Cognitive Deficit
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics